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Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO2) are the key
enzymes of tryptophan (TRP) metabolism in the kynurenine pathway (KP). Both enzymes
function as indicators of immunosuppression and poor survival in cancer patients. Direct
or indirect targeting of either of these substances seems thus reasonable to improve
therapy options for patients. In this study, glioblastoma multiforme (GBM) as well as
head and neck squamous cell carcinomas (HNSCC) were examined because of their
different mechanisms of spontaneous and treatment-induced immune escape. Effects
on gene expression and protein levels were examined. Accompanying assessment of
TRP metabolites from treated GBM cell culture supernatants was conducted. Our results
show a heterogeneous and inversely correlated expression profile of TRP-metabolizing
genes among GBM and HNSCC cells, with low, but inducible IDO1 expression upon IFNγ
treatment. TDO2 expression was higher in GBM cells, while genes encoding kynurenine
aminotransferases were mainly confined to HNSCC cells. These data indicate that the
KP is active in both entities, with however different enzymes involved in TRP catabolism.
Upon treatment with Temozolomide, the standard of care for GBM patients, IDO1 was
upregulated. Comparable, although less pronounced effects were seen in HNSCC upon
Cetuximab and conventional drugs (i.e., 5-fluorouracil, Gemcitabine). Here, IDO1 and
additional genes of the KP (KYAT1, KYAT2, and KMO) were induced. Vice versa, the novel
yet experimental cyclin-dependent kinase inhibitor Dinaciclib suppressed KP in both
entities. Our comprehensive data imply inhibition of the TRP catabolism by Dinaciclib,
while conventional chemotherapeutics tend to activate this pathway. These data point
to limitations of conventional therapy and highlight the potential of targeted therapies to
interfere with the cells’ metabolism more than anticipated.
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INTRODUCTION
Tumor cells release immunosuppressive factors that shape a
tolerogenic environment and enable progression and invasion.
Indoleamine 2,3-dioxygenase (IDO1) is an intracellular
monomeric, immune-checkpoint molecule that degrades
the essential amino acid l-tryptophan along the kynurenine
pathway (KP) (1, 2). Like other immune checkpoints, including
programmed cell death protein 1 and cytotoxic T-lymphocyte-
associated protein 4, IDO suppresses the hosts’ antitumor
immunity by inducing apoptosis in T- and natural killer cells
(3). As a direct consequence of this, many cancer and cancer-
associated cells express IDO1 (mesenchymal stromal cells,
myeloid-derived suppressor cells, dendritic cells, endothelial
cells, tumor-associated macrophages, and fibroblasts) (3–6).
IDO1 is influenced by interferon-γ (IFNγ) (7–9), nitric oxide
(10), pro- [interleukin (IL)-1β, tumor necrosis factor α] and
anti-inflammatory (IL4, IL10, transforming growth factor
β) cytokines. IDO1 activity inhibits T-cell activation and
proliferation and even mediates regulatory T-cell recruitment
to the tumor microenvironment, provoking local immune
tolerance. In head and neck squamous cell carcinomas
(HNSCCs), IDO1 inversely correlates with programmed
cell death protein ligand 1, which constitutes an important
prognostic biomarker for immune-checkpoint inhibition (11).
The increased IDO1 activation decreases intratumoral TRP
levels, resulting in tumor starvation and increase in kynurenine
(KYN) metabolites (which are toxic to lymphocytes) (12). This
immune exhaustion may be further boosted by conventional
chemotherapeutics, leading to decreased efficacy. Therefore,
IDO1 overexpression in the tumor microenvironment intimately
impairs patients’ outcome and may serve as a future prognostic
predictor and drug target (13–18).
In the KP,most studies focused on IDO1 because thismolecule
is amenable to pharmacological intervention (19–22), and a
couple of specific and global IDO inhibitors [including natural
compounds (17, 23, 24)] already entered clinical trials, mostly
reporting safe application and efficacy (stable disease at best
outcome) (25). Current trials are evaluating the efficacy of IDO1
inhibitors in combination with chemotherapy, radiotherapy,
and other immunotherapies including cytotoxic T-lymphocyte-
associated protein 4 blockade (11, 22). The latter is based on
the observation of an enhanced lytic ability of tumor-antigen-
specific T cells upon IDO1 inhibition and decreased numbers
of local immunosuppressive cells such as regulatory T cells
and myeloid-derived suppressor cells (20, 26). The efficacy and
toxicity data from recent clinical trials with IDO1 inhibitors is
reviewed in Yentz and Smith (27). In most cases, however, overall
survival was not significantly improved, leaving the future role
for this combination therapy in question (28). More key enzymes
are involved in TRP metabolism: tryptophan 2.3-dioxygenase
(TDO2), a member of the oxidoreductases family, catalyzes the
same initial step of the KP as IDO1 (2). Thus, TDO2 has been
Abbreviations: CDKi, cyclin-dependent kinase inhibitor; GBM, glioblastoma
multiforme; HNSCC, head and neck squamous cell carcinoma; IDO1, indoleamine
2,3-dioxygenase; IFN, interferon; KYAT, kynurenine aminotransferase; KP,
kynurenine pathway; PBMC, peripheral blood mononuclear cells; SCC, squamous
cell carcinoma; TDO2, tryptophan 2,3-dioxygenase.
shown to be constitutively and highly expressed in various cancer
cells such as malignant glioma and HNSCC (29, 30). More
importantly, TDO2 also has immunomodulatory functions by
promoting immune tolerance. This, in turn, promotes survival,
growth, invasion, and metastasis and decreases patients’ survival
(just like IDO1) (13, 22, 31, 32).
In this study, we performed a comprehensive analysis on the
expression status of genes belonging to the KP. HNSCC and
glioblastoma multiforme (GBM) were picked as prime examples
for different spontaneous and treatment-induced immune escape
mechanisms. Therefore, expression changes were determined
under standard and targeted therapy, and results were compared
among each other.
MATERIALS AND METHODS
Tumor Cell Lines and Culture Conditions
Patient-derived GBM cell lines (N = 13; HROG02, HROG04,
HROG05, HROG06, HROG10, HROG15, HROG24, HROG36,
HROG38, HROG52, HROG63, HROG73, HROG75) and
HNSCC cell lines (N = 6; FADU, Detroit-562, Cal-33,
PE/CA/PJ-15, UT-SCC-14, UT-SCC-15) were either established
and basically characterized in our lab or originally obtained from
the German collection of cell cultures (DSMZ; Braunschweig,
Germany). UT-SCC14 and UT-SCC15 cells were kindly provided
by Prof. R. Grenman [University of Turku, Finland (33)]. All
cells were routinely cultured in our lab and maintained in
full medium: Dulbecco’s modified Eagle Medium/HamsF12
supplemented with 10% fetal calf serum, glutamine (2 mmol/L),
and antibiotics (medium and supplements were purchased from
PAA, Cölbe, Germany). For functional analysis, cell lines from
each tumor entity were chosen, and all subsequent experiments
were performed with these lines only.
IFNγ Stimulation
Cells were cultured in six-well plates or ibidi chamber
slides, incubated overnight and treated with IFNγ
(50 ng/ml, Immunotools, Friesoythe, Germany) for 24
and 72 h, respectively. Thereafter, cells were harvested and
further processed.
Cytostatic Drugs and Targeted Substance
Cytostatics used in this study included 5-fluorouracil (5-FU)
(2.5µM), Cisplatin (0.2µM), Gemcitabine (0.0002µM), and
Cetuximab (0.34µM) for HNSCC, as well as Temozolomide
(10µM, TMZ) for GBM (pharmacy of the University Hospital
Rostock). CDKi Dinaciclib (10 or 100 nM) was used as
experimental targeted drug. All substances were used in doses
below the IC50 as determined before.
Apoptosis/Necrosis Assay
A Yo-Pro-1/PI-based assay for discriminating early apoptotic,
late apoptotic, and necrotic cells was applied as described
before (34).
Hemolysis Assay
Hemolytic activity of Dinaciclib was determined by hemoglobin
release from whole blood cells after 2 h of incubation. Briefly,
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whole blood of healthy donors (N = 5) was seeded in 96-
well plates and treated with increasing Dinaciclib doses (ranging
from 1, 5, and 10µM). Negative controls were left untreated,
and positive controls (=maximum lysis) were treated with
1% sodium dodecyl sulfate. Following the incubation period,
cell-free supernatants were transferred into a new 96-well
plate, and absorption was measured on a plate reader at
560 nm (reference wave length, 750 nm). Hemolytic activity was
quantified according to the following formula and corrected for
spontaneous hemolysis (=untreated controls):
%Hemolysis = ((OD560nmsample
−OD560nmbuffer)/OD560nmmax−OD560nmbuffer)×100
In addition, peripheral blood mononuclear cells’ (PBMC)
viability (N = 5) were determined by Calcein AM staining.
This was done upon 24 h incubation at the above-mentioned
doses. Fluorescence measurement and quantification were done
as described (34).
IDO1 Immunofluorescence
Tumor cells were treated with 50 ng/ml of IFNγ (Immunotools),
TMZ, Cetuximab, or Dinaciclib for 24 h in chamber slides,
respectively. Cells were washed with phosphate-buffered saline,
fixed in 4% paraformaldehyde w/o methanol (Thermo Scientific,
Darmstadt, Germany) for 20min, washed again, followed by
cell permeabilization in 0.3% Triton X−100/5% normal bovine
serum in phosphate-buffered saline for 60min. Cells were then
incubated overnight at 4◦C in monoclonal rabbit IDO1 primary
antibody (1:100; Cell Signaling Technology, Frankfurt/Main,
Germany). Cells were washed, labeled with fluorochrome-
conjugated secondary antibody using goat antirabbit secondary
antibody (1:250, Boster Biological Technology, Pleasanton CA,
USA), and incubated in the dark for 2 h. Cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI), and cells
were analyzed with a Zeiss LSM-780 Confocal Laser Microscope
(Zeiss, Jena, Germany). Quantification of staining intensity
was done using the ImageJ software. Therefore, channels were
split into red, green, and blue. Subsequently, integrated density
profiles of the same size were measured in the green channel.
IDO1 Immunohistochemistry on Patients’
Tumor Samples
Primary antibody against IDO1 (rabbit IgG, clone D5J4E,
Cell Signaling Technology, dilution 1:200) was used. All
samples were pretreated for 20min at 97◦C and pH 6.9.
Standard immunoperoxidase technique was applied using an
automated immunostainer (DAKO link) with diaminobenzidine
as chromogen. IDO1 expressionwas defined as cytoplasmatic and
membranous staining in>1% inflammatory cells.
Quantification of Tryptophan, Kynurenine,
and Kynurenic Acid in Cell Culture
Supernatant by Liquid Chromatography
Tandem Mass Spectrometry System
The basis for the measurement was the method of Fuertig et al.
which was adapted to the system used here (35).
Sample Preparation
Cell culture supernatant was mixed 1:1 with internal
standards [10µM D5-kynurenic acid (Buchem BV, Apeldoorn,
Netherlands), 10µM D5-phenylalanine (Cambridge Isotope
Laboratories, Inc. Andover, MA, United States), 5µM
D4-kynurenine (Cambridge Isotope Laboratories), 10µM
D5-tryptophan (Sigma Aldrich, Hamburg, Germany), 10µM
D3-quinolinic acid (Buchem BV), 5.5 nM 15N5-8-hydroxy-2-
deoxyguanosine (Cambridge Isotope Laboratories)], and with
10 µl of mobile phase (0.4% formic acid, 1% acetonitrile in
water). Reagents were gently shaken on a mixer, and 150 µl
of ice-cold methanol was added. Samples were incubated
overnight at −20◦C to allow protein precipitation. On
the following day, samples were centrifugated at 0◦C and
18,000×g for 15min. Supernatants were transferred to a
new tube, and the liquid phase was removed by evaporation
at 30◦C among vacuum. Solid samples were stored until
measurement at −20◦C. Afterwards, dried extracts were
reconstituted in 100 µl of acidified mobile phase. Samples
were incubated at 40◦C (1 h), centrifuged (4◦C, 18,000×g,
5min), and clear supernatant (100 µl) was transferred onto a
96-well plate.
Liquid Chromatography Tandem Mass Spectrometry
Measurements were performed on an AB Sciex 5500 QTrapTM
mass spectrometer (AB SCIEX, Darmstadt, Germany) with
electrospray ionization in positive mode combined with a
high-performance liquid chromatography system (Agilent 1260
Infinity Binary LC, Santa Clara, United States) including a
degasser unit, column oven, autosampler, and a binary pump.
Twenty microliters of the supernatant was injected and separated
using a VisionHT C18 column (100 × 2.1mm; particle size,
3µm; Grace, MD, United States). To prevent contamination,
a precolumn (VisionHT C18, Guard 5 × 2mm) was used
additionally. The temperature of the column oven was set at
15◦C. The flowrate was set to 0.4 ml/min, and the sample
was separated in a total run time of 11min using solution A
(water + 0.1% formic acid + 0.01% trifluoroacetic acid) and
solution B (MeOH + 0.1% formic acid + 0.01% trifluoroacetic
acid) with the following gradient: 0–2.8min, 97% A, 3% B;
2.8–3.3min, 70% A, 30% B; 3.3–4.4, 40% A, 60% B; 4.5–
5.0min, 40% A, 60% B; 5.0–5.5, 5% A, 95% B; 5.5–6.9min,
5% A, 95% B; 6.9–7.0min, 97% A, 3% B; 7.0–11.0min, 97% A,
3% B.
The eluate between 0.5 and 9min was introduced into the
mass spectrometer and analyzed in MRM mode. The ion spray
voltage (IS) was 4,000V, the curtain gas flow was 40.0 psi, and the
ion source temperature were set at 550◦C.
Internal standards were used for metabolite quantification
(Table 1). Data analysis, including peak integration and
concentration determination, was performed with Analyst
software (Version 1.5.1, AB Sciex, Darmstadt, Germany).
RNA Isolation, cDNA Synthesis, and
Quantitative Real-Time PCR
Total RNA was isolated with RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturers’ instructions. RNA
was reverse transcribed into complementary DNA (cDNA) from
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1 µg RNA using 1 µl dNTP mix (10mM), oligo (dT)15
primer (50 ng/µl), 1 µl reverse transcriptase (100U), and 4
µl 5× reverse transcription buffer complete (all purchased
from Bioron GmbH, Ludwigshafen, Germany). Final reaction
volume was 20 µl (filled with RNAse free water). cDNA
synthesis conditions were as follows: 70◦C for 10min, 45◦C
for 120min, and 70◦C for 10min. Target cDNA levels of
human cell lines were analyzed by quantitative real-time PCR
using TaqMan Universal PCR Master Mix and self-designed
TaqMan gene expression assays either labeled with 6-FAM-3′
BHQ-1 or 5′ HEX−3′ BHQ-1 to be used as duplex: IDO1,
TDO2, KMO, HAAO, KYAT1/2/3/4, KYNU, QPRT, and GAPDH
TABLE 1 | Internal standards.
Analyte Q1 mass (m/z) Q3 mass (m/z) CE (V) DP (V)
Tryptophan 205.1 118.0 28.0 39.0
d5-Tryptophan 210.1 122.1 37.0 31.0
Kynurenine 209.1 94.1 19.6 41.0
d4-Kynurenine 213.1 140.1 21.0 39.0
Kynurenic acid 190.1 162.0 24.0 65.0
d5-Kynurenic acid 195.1 167.1 24.0 65.0
or ß-actin were used as housekeeping genes. Reaction was
performed in the light cycler Viia7 (Applied Biosystems, Foster
City, USA) with the following PCR conditions: 95◦C for
10min, 40 cycles of 15 s at 95◦C, and 1min at 60◦C. All
reactions were run in triplicates. The messenger RNA (mRNA)
levels of target genes were normalized to GAPDH/β-actin.
Reactions were performed in triplicate wells and repeated
four times. The general expression level of each sample
was considered by calculating 2−1CT (1Ct = Cttarget –
CtHousekeeping genes).
Statistical Analysis
All values are reported as mean ± SD. After proving the
assumption of normality, differences between controls and
treated cells were determined using the unpaired Student’s t-
test. If normality failed, the non-parametric Mann-Whitney U-
test was applied. Statistical evaluation was performed using
GraphPad PRISM software, version 5.02 (GraphPad Software,
San Diego, CA, USA). In case of multiple comparisons, two- or
one-way ANOVA on ranks (Bonferroni’s multiple comparison
test) was used. The criterion for significance was taken
to be p< 0.05.
FIGURE 1 | Relative messenger RNA (mRNA) expression of IDO1, TDO2, KYNU, KYAT2, KYAT3, and KYAT4 in glioblastoma multiforme (GBM) and head and neck
squamous cell carcinoma cells (HNSCC). The graphs indicate the mRNA expression normalized to the housekeeping genes (2−1CT). GBM (N = 13, HROG02,
HROG04, HROG05, HROG06, HROG10, HROG15, HROG24, HROG36, HROG38, HROG52, HROG63, HROG73, HROG75) and HNSCC cell lines [N = 6; FADU,
Detroit-562, Cal-33, PE/CA/PJ-15, UT-SCC14, UT-SCC-15 (33)].
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FIGURE 2 | IDO1 immunohistochemistry. Representative images of primary glioblastoma multiforme (GBM) [HROG36 (a,b), HROG63 (c,d), and HROG73 (e,f)] and
head and neck squamous cell carcinoma (HNSCC) [HNSCC06 (g,h), HNSCC02 (i,j), HNSCC01 (k,l)] samples. Left panel: Routine HE staining. Right panel: Note the
focal IDO1 expression on tumor-infiltrating lymphocytes exclusively in HNSCC cases. HNSCC case 1 (g,h): tonsil (HPVpositive); case 2 (i,j): mouth base (HPVnegative,
relapse); case 3 (k,l): larynx (HPVnegative). Pictures were taken at 20× and 10× magnification, respectively.
RESULTS
Basal IDO1 and Related Genes in GBM and
HNSCC Cell Lines
While IDO1 itself is not the only mechanism by which tumors
can resist immune-mediated killing, we studied the expression
status of different KP-related genes on a panel of human
GBM and HNSCC cell lines. These experiments revealed not
only differences between both entities but also a heterogeneous
profile of all tested genes among cell lines (Figure 1). IDO1
was differently expressed by most glioma samples (11/13)
analyzed. In general, IDO1 was only detectable at very low levels
(Figure 1). TDO2, the other rate-limiting enzyme of the KP
(36), was constitutively expressed by all glioma samples, and
expression was even higher in comparison to IDO1. Generally,
expression status for TDO2 and kynurenine hydrolase (KYNU)
was higher in GBM, while HNSCC expressed more kynurenine
aminotransferases (KYAT) (Figure 1). Hence, these data indicate
that the KP is active in both entities, with however different
enzymes being involved in TRP catabolism.
Still, tumor cell lines grown in vitro not necessarily
represent the in vivo situation; we therefore analyzed the IDO1
abundance in clinical resection specimens (Figure 2). In GBM,
IDO1 was detectable in one of three cases (representative
images are shown in Figure 2). By contrast, HNSCC samples
presented with IDO1 but only on a small fraction of tumor-
infiltrating lymphocytes (Figure 2). Although not analyzed
systematically, the only HPVpositive case in this small cohort
showed highest IDO1 abundance, nicely reflecting the tumors’
immunogenicity (11, 37).
Gene Expression and Protein Changes
Upon IFNγ Stimulation
IDO1 is an IFNγ-inducible enzyme. Upon stimulation,
the KP is activated to induce immunosuppression. In vitro
stimulation with IFNγ mimics the in vivo situation of an
inflammatory microenvironment. Hence, upon immune-
mediated inflammation, IDO1-negative tumor cells may
upregulate IDO1 as resistance mechanism.
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FIGURE 3 | Relative messenger RNA (mRNA) expression of IDO1, TDO2, KYNU, KYAT2, KYAT3, and KYAT4 as well as IDO1 protein abundance following interferon-γ
(IFNγ) stimulation in glioblastoma multiforme (GBM) and head and neck squamous cell carcinoma (HNSCC) cells. The cell cultures were either untreated or treated
with IFNγ (50 ng/ml) for 24 h. (A) The graphs indicate the mRNA expression normalized to the housekeeping genes (2−1CT). GBM N = 5 cell lines (HROG02,
HROG05, HROG52, HROG63, HROG75); HNSCC, N = 4 cell lines (FADU, Detroit-562, Cal-33, PE/CA/PJ-15). (B) IDO1 immunofluorescence in selected cell lines.
Cell nuclei were stained with DAPI, and IDO1 was depicted by monoclonal rabbit IDO1 primary antibody (1:100; Cell Signaling Technology), followed by secondary
antibody (1:250, Boster Biological Technology Pleasanton, CA, United States) labeling. Cells were analyzed with a Zeiss LSM-780 Confocal Laser Microscope.
Original magnification 20×.
Using five individual GBM cell lines, IDO1 expression was
inducible in all cases (Figure 3A). Upregulation of IDO1was high
on protein levels in HROG05 cells and marginal in HROG63
(Figure 3B). TDO2 and KYAT3 were suppressed upon IFNγ
stimulation in three of five samples and hardly detectable in one
cell line, supporting data from a recent publication (38). KYNU
was not affected by IFNγ stimulation (Figure 3A).
Just as in GBM, IDO1 was inducible in HNSCC cells
(Figure 3A). Immunofluorescence revealed focal expression of
singular cells with different intensity (Figure 3B). Of note,
IFNγ stimulation even induced upregulation of KYAT1, KYAT2,
KYAT3, and KYAT4 (Figure 3A and data not shown), most likely
constituting a compensatory mechanism as described before in
experimental autochthonous tumor models (39).
Interference With the KP of Cytostatic and
Targeted Therapies
Next, we examined whether cytostatic and targeted drugs have
an influence on the KP. For GBM, TMZ was chosen, and for
HNSCC, 5-FU, Cisplatin, Gemcitabine, as well as Cetuximab
were used. As a targeted yet still experimental agent, the potent
and specific CDKi Dinaciclib was applied to cells of both entities.
Before this experiment, drug doses were carefully tested
in dose-response analyses (data not shown) along with
discrimination of apoptosis and necrosis. Generally, drugs used
in this study tended to induce necrosis, while apoptosis, if
present, was only detectable at early time points. Exemplary
results for the HNSCC cell line Detroit-562 are given in
Supplementary Figures 1A,B. While cytostatics are well-known
to affect normal cells’ viability, the impact of the CDKi
Dinaciclib on immune and red blood cells is less clear.
We therefore performed a hemolysis and leukocyte viability
assay. In this experiment, no toxicity was seen against normal
cells (Supplementary Figure 1C). Even at high concentrations,
Dinaciclib impaired cellular viability/integrity only marginally
(Supplementary Figure 1C).
TMZ is an oral alkylating agent that methylates DNA
at the O6 position of guanine causing cell cycle arrest at
G2/M. It is used as standard of care for GBM. However,
acquired resistance, a process not fully understood, leads to
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FIGURE 4 | Relative messenger RNA (mRNA) expression of IDO1, KYAT1, KYAT2, KYAT3, KYAT4, and KMO upon cytostatic drugs and targeted therapy in
glioblastoma multiforme (GBM) cells. Graphs indicate the mRNA expression of selected kynurenine pathway (KP)-related genes normalized to the housekeeping
genes (2−1CT). Results show data of three independent experiments. *p < 0.05; **p < 0.01 vs. control. Two-way ANOVA.
major limitations in treatment. Here, TMZ downregulated
IDO1 in three of five GBM cell lines but led to increased
expression in HROG52 and HROG63—a paired GBM cell line
established from the very same patient (primary lesion and
upon relapse) (Figure 4). Gene expression of KYAT2, KYAT4,
and KMO was heterogeneous. Generally, there was a trend
toward higher expression of those genes but with cell-line-
specific differences (e.g., KYAT3: p < 0.05 vs. control in
HROG05 cells; Figure 4). KYNU expression was not affected
by TMZ (data not shown). Interestingly, the combination
of IFNγ and TMZ that mimics the in vivo situation led
to similar or even stronger IDO1 upregulation compared to
IFNγ alone in two out of four glioma samples (Figure 5).
Adding Dinaciclib to either IFNγ or TMZ lowered the mRNA
expression of IDO1 massively. Other KP-related genes like
TDO2 and KYAT1-4 were similarly downregulated (Figure 5).
Supplementary Table for Figure 5 provides a detailed statistical
analysis of each cell line in relation to the individual
treatment regimens.
In HNSCC cells, Cetuximab was the only IDO1-inducing
substance (exemplary results for Detroit-562 cells are given in
Figure 6). Beyond that, the cytostatics as well as Cetuximab
induced at least one of the KP-related genes (p < 0.05 vs.
control), implicating activation of this pathway via different
effectors. By adding Dinaciclib to cytostatic drugs, this effect
was abrogated, even in the presence of IFNγ (Figure 6 and
data not shown). Of note, Dinaciclib alone as well as in
combination with other substances effectively suppressed all KP-
related genes, implying inhibition of the TRP catabolism by
this CDKi.
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FIGURE 5 | Relative messenger RNA (mRNA) expression of IDO1, TDO2, KYAT1, KYAT2, KYAT3, and KYAT4 upon concomitant treatment with interferon-γ (IFNγ) and
cytostatic drugs in glioblastoma multiforme (GBM) cells. The cell cultures (N = 5, HROG02, HROG05, HROG52, HROG63, HROG75) were either left untreated or
treated with IFNγ (50 ng/ml) for 24 h. Treatments were performed simultaneously, i.e., IFNγ ± TMZ, and/or Dinaciclib. Graphs indicate the mRNA expression of
selected KP-related genes normalized to the housekeeping genes (2−1CT). Results show data of three independent experiments. A statistical report is given in
Supplementary Table for Figure 5.
Dinaciclib Blocks IFNγ-Induced IDO1
Expression in GBM and HNSCC Cells
Considering the active downregulation of KP-related genes by
Dinaciclib, we investigated whether this CDKi is able to inhibit or
reverse IFNγ-induced IDO1 upregulation in GBM and HNSCC
cells on a protein level. TMZ and Cetuximab were included as
active inductors of IDO1 and associated KP-related genes.
IFNγ and selected drugs were added simultaneously for 72 h.
Dinaciclib effectively blocked IFNγ-induced IDO1 protein in
both entities, while TMZ alone as well as the combination with
IFNγ strongly enhanced IDO1 protein level (Figure 7). Hence,
mRNA expression data were nicely confirmed.
When Dinaciclib was combined with IFNγ and TMZ, the
IDO1-inducing stimulus of these latter substances was far too
strong to be suppressed (Figure 7). However, the low number of
residual cells in this combination hints toward additive or even
synergistic effects independent from IDO1 (Figures 7A,B).
While IDO1 was highly inducible in GBM cells only, we then
determined protein level upon IFNγ-prestimulation approaching
the in vivo situation. The cytotoxic effect of Dinaciclib was
preserved; however, levels of IDO1 enzyme were not significantly
altered (Supplementary Figures 2A,B). Comparable results were
obtained for TMZ. Virtually, all residual cells showed positive
staining; still there was a trend toward lower intensity in
monotherapy and in combination (Supplementary Figure 2B).
Taken together, the CDKi Dinaciclib is able to block IFNγ-
mediated and thus most likely even chemotherapy-induced
IDO1 upregulation in GBM and HNSCC cells. However, blunt
interference with this TRP-metabolizing enzyme is unlikely.
Treatment Induced Influence on
KP-Related Metabolites
Our data revealed IDO1 induction by TMZ, which is reversible
by Dinaciclib. Thus, we examined the influence on KP-related
metabolites in GBM cell lines.
TRP, KYN, and the downstream metabolite kynurenic acid
(KYNA) were quantified by MS using cell culture supernatants
of GBM cell lines (Figures 8A,B). TRP was catabolized
after 24 h from all cell lines among all treatment regimens.
Adding TMZ or Dinaciclib in monotherapy marginally affected
TRP consumption as well as KYN and KYNA production.
Stimulation with either IFNγ or a combination of TMZ
resulted in greatly enhanced TRP depletion and increased
KYN levels, although to varying degrees in the different cell
lines (Figure 8A). Small amounts of KYNA were produced
constitutively and to a greater extent after IFNγ mono- and TMZ
combination in all cell lines (Figure 8A). In contrast, KYNA level
remained unchanged uponDinaciclib in combination with IFNγ,
confirming immunofluorescence results (please see Figure 7 for
details). The same was true for the KYN/TRP ratio, being only
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FIGURE 6 | Relative messenger RNA (mRNA) expression of IDO1, KYAT1, KYAT2, KYAT3, KYAT4, and KMO upon cytostatic drugs and targeted therapy in head and
neck squamous cell carcinoma (HNSCC) cells. Graphs indicate the mRNA expression of selected KP-related genes normalized to the housekeeping genes (2−1CT).
Results show data of three independent experiments using HNSCC cell line Detroit-562. *p < 0.05; **p < 0.01. One-way ANOVA (Bonferroni’s multiple
comparison test).
affected in samples treated with IFNγ as well as the combination
of IFNγ and TMZ (Figure 8B).
These data underline our gene and protein expression
data. The CDKi Dinaciclib is directly or indirectly capable of
blocking the KP. TMZ particularly in combination with the
proinflammatory cytokine IFNγ accelerates TRP consumption
accompanied by KYN and KYNA production in GBM cells.
DISCUSSION
The finding that high IDO1 expression is associated with
shorter survival in cancer patients made IDO1 a promising target
either by specific inhibitors or indirectly by immunomodulation.
A recent study described dramatically suppressed tumor growth
upon IDO1 knockdown by increasing the number of CD4+
and CD8+ T cells in murine GBM models (9). However, the
exact mechanisms underlying IDO1 and thus TRP metabolism
along the KP remain unclear. Therefore, we focused on the
expression of IDO1 and IDO-related KP genes and their potential
involvement in immune evasion in experimental models of
HNSCC and GBM.
We were able to show that the KP is active in both entities,
with different enzymes involved in TRP catabolism. Of note,
basal IDO1 expression was low and inversely correlated with
TDO2. In the only prior study on primary GBM cultures, similar
results were described with constitutive TDO2 expression in
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FIGURE 7 | Indoleamine 2,3-dioxygenase (IDO1) protein abundance in selected glioblastoma multiforme (GBM) and head and neck squamous cell carcinoma
(HNSCC) cells upon cytostatic drugs and targeted therapy. The cell cultures [(A) GBM: HROG05; (B) HNSCC: Detroit-562] were either left untreated or treated with
IFNγ (50 ng/ml) for 24 h. Treatments were performed simultaneously, i.e., IFNγ ± TMZ, Cetuximab, and/or Dinaciclib. Cell nuclei were stained with DAPI. Original
magnification 20×. (C,D) Quantification was done to score staining intensity in untreated and treated HROG05 and Detroit-562 cells. This was carried out using
ImageJ software as described in Material and Methods.
most GBM cell cultures (29). In here, TDO2 likely promotes
tumor growth by suppressing antitumor immune responses
(2, 31). KP products are considered as therapeutic targets
because IDO1 and other genes of the TRP metabolism are not
expressed in healthy brain tissue, but gradually increase with
GBM dedifferentiation (low vs. high grade GBM). In HNSCC,
different results on IDO1 are documented, and expression is
heterogeneous among different HNSCC cell lines. Of note, IDO1
abundance of primary resection specimen and cultured cells
seems to be independent from anatomical site and HPV status
(40). Still, IDO1 is a useful marker for progression of in oral
squamous cell carcinoma (41). In esophageal squamous cell
carcinoma, progression and metastasis correlates with strong
inflammation at the tumors’ invasive front and disturbed TRP
metabolism (42). These cumulative data highlight the biological
relevance of the KP inmalignancies andmay explain why IDO1 is
barely detectable upon long-term in vitro culture. By mimicking
the inflamed microenvironment and thus taking a step closer to
the in vivo situation, IFNγ was added as strong IDO1 inductor
(43). While GBM cells responded with the expected IDO1
upregulation on mRNA expression and protein level as well as
accelerated TRP consumption, this molecule was barely inducible
in HNSCC cells. It is conceivable that this is due to the duration
of in vitro culture. GBM cells were established recently and thus
used in defined low passages (<P40), whereas half of the HNSCC
cell lines were long-term cultures with more or less unknown
passage [Detroit-562 as well as UT-SCC14 and UT-SCC15 (44)
are the only exceptions;<P40]. Cell lines may acquire additional
mutations overtime changing their protein expression. Another
in vitro limitation is that experiments were conducted without
immunological pressure. In vivo studies are desirable to verify
the results.
Indirect effects of TRP metabolism include interference
with other biological functions like migration, angiogenesis,
and cell growth regulation (18, 40). To investigate the
influence of anticancer drugs on TRP catabolism, we performed
a comprehensive analysis using conventional chemotherapy
(TMZ, 5-FU, Cisplatin, Gemcitabine) and targeted drugs
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FIGURE 8 | Indoleamine 2,3-dioxygenase (IDO) protein abundance in glioblastoma multiforme (GBM) and head and neck squamous cell carcinoma (HNSCC) cells as
well as kynurenine pathway (KP) metabolite levels in GBM cells upon cytostatic drugs and targeted therapy. Treatments were performed sequentially, i.e., interferon-γ
(IFNγ) pretreatment for IDO1 induction, followed by Temozolomide (TMZ) and/or Dinaciclib. (A) KP metabolites changed upon TMZ but not Dinaciclib treatment. The
combination of TMZ and IFNγ accelerates tryptophan (TRP) consumption accompanied by kynurenine (KYN) and kynurenic acid (KYNA) production (B). KYN/TRP
ratios in GBM cells were determined dividing KYN values by TRP values. Results show data of a single measurement.
(Cetuximab, Dinaciclib). The KP-related gene expression and
metabolites were determined in residual cells. In GBM, the
standard of care drug TMZ was applied either with or without
IFNγ stimulation. While this substance affected IDO1 on the
expression level, the amount of the resulting protein increased.
This may be explained by either increased protein’s half-life due
to a reduced rate of degradation or the preferential translation
during cellular stress. In previous studies, exposure of several
cultured human malignant glioma cell lines, primary neurons,
and a neuroblastoma cell line to IFNγ reduced TRP levels in
culture medium accompanied by increased IDO1 expression and
KYN production (29, 45). Our results confirm these data, and in
addition, we were able to demonstrate that IFNγ stimulation in
combination with TMZ stimulated KYN and KYNA production
and TRP catabolism in GBM cell cultures. The increase in TRP
catabolism and KYN production (KYN/TRP ratio) is widely used
as indirect indicator of the cumulative activities of TDO2, IDO1,
and IDO-2 (38, 46). The KP in brain tumors is likely triggered
by IFNγ from immediate surrounding tissue (29, 47, 48). Thus,
IDO1 expression in brain tumor cells is likely to be triggered
when IFNγ is produced from activated T cells and/or microglia
and neurons. Furthermore, gliomas and glioneuronal tumors
have an elevated tryptophan uptake and catabolism in vivo (49).
Given our observation on a further enhanced KP activity upon
TMZ treatment, this might provide an explanation of (acquired)
drug resistance and final relapse. Hence, IDO1 blocking agents
should be investigated in TMZ-tailored therapeutic approaches.
In HNSCC cells, KP activation was different. KP-related
genes were exclusively induced by standard drugs, and only
Cetuximab induced IDO1. Additional upregulated genes
involved kynurenine aminotransferases, responsible for
synthesizing a neuroprotectant, and KMO. While the specific
biochemical activity of these molecules and biological relevance
in cancer is barely examined, we interpret this result as one
possible mechanism of resistance upon therapy—a finding quite
common after conventional chemotherapy and usually also
being associated with poor response toward neoadjuvant therapy
in other entities (50).
Mechanistically, this can be attributed to the secretion of
proinflammatory substances, such as prostaglandin E2 or high-
mobility group protein B1 by dying tumor cells, secondary
contributing to KP activation. By accumulating TRP, toxic
metabolites of tumor cells actively shape an immunosuppressive
microenvironment. Breaking down this shield is one of the main
objectives in pharmacological inhibition of KP. Questions remain
why most inhibitors failed in clinical trials, and mechanisms are
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only just beginning to become clear. A fact worth mentioning
is the functional redundancy of IDO1, IDO-2, and TDO2 (51),
augmenting the risk of mechanistic bypass.
Dinaciclib is a potent and specific CDK inhibitor of CDK1,
CDK2, CDK5, and CDK9. Preclinical studies showed that this
inhibitor is capable of decelerating tumor growth in numerous
cancer entities via cell cycle arrest and apoptosis induction (52,
53). In our study, Dinaciclib was the only KP-inhibiting substance
tested here. Of note, impairment of the KP was independent from
the combination partner, and this CDKi effectively suppressed
IFNγ-induced IDO1 upregulation after simultaneous treatment.
While this result was completely unexpected and has—to the
best of our knowledge—not been described previously, our data
do not support the idea of blunt interference with the KP.
GBM cells with strong IDO1 expression showed only marginally
reduced IDO1 protein level after Dinaciclib treatment. This
effect might be boosted after long or repeated treatment cycles.
In line with these findings, several preclinical studies already
proposed synergistic effects of selective and unselective IDO1
inhibitors when administered in conjunction with chemo- and/or
radiotherapy (4). This may finally have impact for second-
or third-line immunotherapeutic approaches. Therefore, the
late KYN/TRP index is indeed a relevant clinical benchmark
providing prognostic value for GBM patients (54).
Summarizing our findings, we provide evidence for the
relevance of TRP catabolism in malignancies especially in the
context of standard therapy. The CDKi Dinaciclib was identified
as indirect KP inhibitor. Lastly, specific KP inhibition may
increase the efficacy of standard drugs by restoring immune
function and thus improve patients’ outcome.
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Supplementary Figure 1 | Quantitative analysis of cell death in Detroit-562
HNSCC cells upon cytostatic drugs and targeted therapy. The cells were treated
with the given substances for 24 and 72 h. Thereafter, cells were harvested and
stained with Yo-Pro-1 to detect early and late apoptotic cells, as well as propidium
iodide for necrosis determination. Apoptosis/necrosis discrimination was done on
a flow cytometer (BD FACSVerseTM) as described in material and methods.
(A) Quantitative analysis of cell death after 24 and 72 h, respectively. ∗p < 0.05 vs.
control; ∗∗p < 0.01 vs. control. t-test. (B) Representative dot plots showing
elevated numbers of necrotic cells upon treatment. (C) Hemolysis and viability of
PBMC upon treatment with Dinaciclib. Therefore, whole blood and PBMC were
cultured in the presence of increasing Dinaciclib concentrations (1, 5, and 10µM)
for 2 and 24 h, respectively. Hemolytic activity was determined from cell-free
supernatants (red blood cell lysis), Calcein AM was used for quantifying viability of
PBMC. Mean + SD, N = 5 individual donors.
Supplementary Figure 2 | IDO1 protein abundance in HROG05 GBM cells upon
cytostatic drugs and targeted therapy. The cells were pretreated with IFNγ
(50 ng/ml) for 24 h. Thereafter TMZ, Dinaciclib and the combination of both
substances was added to see whether IFNγ-induced upregulation of IDO1 is
reversible. (A) None of these substances downregulated IDO1 in the sequential
setting. Cell nuclei were stained with DAPI. Original magnification 20x.
(B) Quantification was done to score staining intensity in untreated and treated
HROG05 cells. This was carried out by using ImageJ software as described in
material and methods.
Supplementary Table for Figure 5 | Statistical analysis of individual treatment
regimens, depicted for each cell line, and genes analyzed.
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